Monday, 23 September 2013

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study)

Although the primary outcome was not met, at 12 months, alefacept preserved the 4 h C-peptide AUC, lowered insulin use, and reduced hypoglycaemic events, suggesting efficacy. Safety and tolerability were similar in the alefacept and placebo groups. Alefacept could be useful to preserve ß-cell function in patients with new-onset type 1 diabetes (The Lancet Diabetes & Endocrinology)

No comments:

Post a Comment